This post was originally published on this site

[unable to retrieve full-text content]Aimmune Therapeutics Inc AIMT.O shareholders have backed Nestle’s NESN.S $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow …